I cant seem to find a bad word about melatonin, or anyone saying 3mg or higher is a high dose.
you sure you on top of this necro ?
ya for sleep induction and quality the lower dose seems to work best. However, there have been studies with melatonin in the close to gram range for long periods showing no ill effects. Also, im not against taking higher doses as i once stated, after continual usuage the next day hypersomnolence is gone. Also, it is a potent antioxidant and with the safety data higher doses offer potential health benefits. I mentioned this before but for people with GERD, you may want to try 6-9 mgs of melatonin a day to reduce symptoms, it is quite effective and validated by research. There has been quite a bit of research on cancer and melatonin and the possible treatment of such. I think it is a great supplement and if treating solely insomnia, i would still recommend the lower dosing.
Hypertens Res. 2009 Oct 30. [Epub ahead of print]
Melatonin for nondippers with coronary artery disease: assessment of blood pressure profile and heart rate variability.
Rechciński T, Trzos E, Wierzbowska-Drabik K, Krzemińska-Pakuła M, Kurpesa M.
Department of Cardiology, Biegański Hospital, Medical University of Lodz, Lodz, Poland.
The aim of this study was to assess the effects of 5 mg melatonin before sleep in patients with coronary artery disease (CAD) and with an abnormal circadian pattern of blood pressure (BP) on changes in circadian BP profile and heart rate variability (HRV). Sixty patients with CAD, nondippers aged 48-80 years (male 75%), were included. In addition to previous treatment, they were randomly allocated to melatonin or placebo. After 90 days, a second 24-h BP monitoring was carried out. Each patient had two sessions (before randomization and at the end of study) of 24-h ECG monitoring to assess the changes in HRV. Inclusion of melatonin led to BP pattern normalization in 35% of patients in the melatonin group and in 15% of controls (P=0.609). This effect was reached not only by a decrease in nighttime BP, but also by an increase in daytime BP (significant in the melatonin group). A nonoptimal effect for BP profile was observed in 12.5% of patients: extreme- or reverse dippers. In patients with conversion from nondippers to dippers (responders), an increase in standard deviation of normal-to-normal intervals between initial and final HRV analyses was observed. Nonresponders represented an increase in the mean circadian heart rate. To avoid nonoptimal effects, the inclusion of melatonin in pharmacotherapy of patients with CAD should be based on monitoring of circadian BP profile, before and during treatment.
As melatonin caused not only a nocturnal decrease in BP but also a daytime increase, it should not be recommended in patients with 'high normal' values of BP because of the danger of induction of arterial hypertension.Hypertensio n Research advance online publication, 30 October 2009; doi:10.1038/hr.2009.174melatonin and its relationship to blood pressure. Sorry guys there is a shit ton of research but im so sedated right now i dont think i can weed through it much more. If anyone wants more info on melatonin or research for general knowledge just request it. i have absolutely no problem helping, i rather enjoy learning about possible therapies.
Postepy Hig Med Dosw (Online). 2009 Sep 15;63:425-34.
[MT1 melatonin receptors and their role in the oncostatic action of melatonin]
[Article in Polish]
Danielczyk K, Dziegiel P.
Katedra i Zakład Histologii i Embriologii Akademii Medycznej im. Piastów Slaskich we Wrocławiu.
Melatonin, the main hormone produced by the pineal gland, strongly inhibits the growth of cancer cells in vitro and in vivo. Some publications indicate that the addition of melatonin to culture medium slows the proliferation of some cancer cell lines. It is also suggested that melatonin used as an adjuvant benefits the effectiveness and tolerance of chemotherapy. The mechanisms of this are not fully understood, but melatonin receptors might be one of the most important elements. Two distinct types of membrane-bound melatonin receptors have been identified in humans: MT1 (Mel1a) and MT2 (Mel1b) receptors. These subtypes are 60% homologous at the amino-acid level. MT1 receptors are G-protein-coupled receptors. Through the a subunit of G protein, melatonin receptors stimulate an adenylate cyclase and decrease the level of cAMP. This has a significant influence on cell proliferation and has been confirmed in many tests on different cell lines, such as S-19, B-16 murine melanoma cells, and breast cancer cells. It seems that expression of the MT1 melatonin receptors benefits the efficacy of melatonin treatment. Melatonin and its receptors may provide a promising way to establish new alternative therapeutic approaches in human cancer prevention.
some research on cancer(above and below).
Br J Cancer. 2009 Nov 3;101(9):1613-9. Epub 2009 Sep 22.
Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells.
Martínez-Campa C, González A, Mediavilla MD, Alonso-González C, Alvarez-García V, Sánchez-Barceló EJ, Cos S.
Department of Physiology and Pharmacology, School of Medicine, University of Cantabria, 39011 Santander, Spain.
BACKGROUND: Melatonin reduces the development of breast cancer interfering with oestrogen-signalling pathways, and also inhibits aromatase activity and expression. Our objective was to study the promoters through which melatonin modifies aromatase expression, evaluate the ability of melatonin to regulate cyclooxygenases and assess whether the effects of melatonin are related to its effects on intracellular cAMP, in MCF-7 cells. METHODS: Total aromatase mRNA, aromatase mRNA promoter regions and cyclooxygenases mRNA expression were determined by real-time RT-PCR. PGE(2) and cAMP were measured by kits. RESULTS: Melatonin downregulated the gene expression of the two major specific aromatase promoter regions, pII and pI.3, and also that of the aromatase promoter region pI.4. Melatonin 1 nM was able to counteract the stimulatory effect of tetradecanoyl phorbol acetate on PGE(2) production and inhibit COX-2 and COX-1 mRNA expression. Melatonin 1 nM elicited a parallel time-dependent decrease in both cyclic AMP formation and aromatase mRNA expression. CONCLUSIONS: This study shows that melatonin inhibits aromatase activity and expression by regulating the gene expression of specific aromatase promoter regions. A possible mechanism for these effects would be the regulation by melatonin of intracellular cAMP levels, mediated by an inhibition of cyclooxygenase activity and expression.
cool thing about this study is it confirms that melatonin is an anti-estrogen via inhibiting testosterone aromatization. Anyway i want to examine the role of melatonin on GH production as topically it is synergistic with GH in osteoblastic(bone building) activity. I have a look tom, im zonked.